Compare RENT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RENT | CLLS |
|---|---|---|
| Founded | 2009 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.6M | 103.8M |
| IPO Year | 2021 | 2014 |
| Metric | RENT | CLLS |
|---|---|---|
| Price | $1.73 | $0.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.45 |
| AVG Volume (30 Days) | ★ 854.2K | 55.6K |
| Earning Date | 12-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 110.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $329,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.71 | N/A |
| 52 Week Low | $1.51 | $0.88 |
| 52 Week High | $10.13 | $5.45 |
| Indicator | RENT | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 37.29 | 37.12 |
| Support Level | $1.51 | N/A |
| Resistance Level | $1.89 | $1.28 |
| Average True Range (ATR) | 0.22 | 0.12 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 3.95 | 0.00 |
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe to, or buy designer apparel and accessories. The company gives customers access to its unlimited closet through its subscription offering (Subscription) or the ability to rent a-la-carte through its reserve offering (Reserve). The company also gives its subscribers and customers the ability to buy its products through its Resale offering. The Closet in the Cloud offers a wide assortment of items for every occasion, from evening wear and accessories to ready-to-wear, workwear, denim, casual, maternity, outerwear, blouses, knitwear, loungewear, jewelry, handbags, activewear, and ski wear.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.